Study of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban

• Status: Completed
• Trial end date: 2020-08-26
• Target enrollment: 0
• Participant gender: All

Summary

Evaluation of the performance of the 2MACE index in a population of nonvalvular atrial fibrillation (NVAF) patients treated with rivaroxaban in Spain

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Collaborator: Janssen Research & Development, LLC
• Treatments: Rivaroxaban

Criteria

Inclusion Criteria:

• Adult patients aged 18 years or older.

• Patients with diagnosis of NVAF.

• Patients treated with rivaroxaban from at least six months prior to the study inclusion.

• Patients who have been given appropriate information about the study objectives and procedures and who have given their written informed consent.

Exclusion Criteria:

• Patients participating in an investigational program with interventions outside of routine clinical practice.

• Patients who initiate treatment with rivaroxaban after the start of the study inclusion period.

• Prosthetic heart valves or the presence of any severe valvulopathies.

• Patients with severe cognitive impairment.

• Patients with chronic infections (HIV infection, hepatitis C virus, hepatitis B virus) or systemic autoimmune diseases.

• Patients with active cancer.

• Patients with liver insufficiency (eg. cirrhosis).